Q-omics provides the consensus-scored LINC01764 profile across patient tissues and cancer cell-line models. LINC01764 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC01764 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, LINC01764 RNA expression shows 7,767 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight HNSC, and BLCA as cancer lineages where LINC01764 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01764 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01764 survival associations across molecular data types. LINC01764 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01764 RNA expression–survival associations across cancer types. High LINC01764 expression shows unfavorable associations in HNSC and COAD, but favorable associations in UVM, CESC, MESO and LAML. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC01764 RNA expression.
This table summarizes LINC01764 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01764. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01764 shows lower tumor expression in KICH, KIRC and THCA and higher tumor expression in BLCA, COAD and HNSC. The BLCA box plot shows higher LINC01764 RNA expression in tumor versus normal tissue (log2 FC = +0.902, t-test p = .009).
This table shows molecular features associated with LINC01764 in patient tissues and cancer cell lines. In patient samples, LINC01764 shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set.
